Acute COVID-19 has a great range of clinical severity from asymptomatic to fatal.

In the absence of clinical trials and guidelines, and with hospitalizations and mortality mounting, we must deploy treatment for COVID-19 based on pathophysiological principles.

As a result, Dr. McCullough developed a renowned protocol based on age and co-morbidities that allows for many people to be monitored and treated at home during self-isolation -- reducing the risks of hospitalization and death.

In March 2020, Dr. Zelenko’s team was one of the first in the country to successfully treat thousands of Covid-19 patients in the prehospital setting utilising the Zelenko Protocol. 

Dr. Zelenko wrote that "it is essential to start treatment against Covid-19 immediately upon clinical diagnosis of the infection and not to wait for confirmatory testing. There is a very narrow window of opportunity to eliminate the virus before pulmonary complications begin. Delaying treatment is the essence of the problem. My treatment regime ... has saved thousands of patients without serious complications or negative side effects."

​

He produces a range of supplements here.

The following is the protocol Drs. Fareed and Tyson have jointly developed as most effective for their COVID-19 patients.

They successfully treated and saved over 7,000 lives in their clinics and more than 1,200 in the Trinity Baptist Church C19 advocacy.

Fareed/Tyson COVID-19 Treatment Protocol

HCQ 200 mg tabs #16 (HCQ = hydroxychloroquine)

Zinc sulfate 22O mg (or elemental Zinc 50 mg) # 15

Azithromycin 500 mg # 5 (or Z pack) or

Doxycycline 100 mg # 10)

Ivermectin 3 mg tabs #8

Aspirin 325 mg tabs #30 

A Summary Statement By Rob Rennebohm, MD 

​

Treatment of COVID-19 with IVM has been far more extensively and carefully studied than has treatment of COVID-19 with Paxlovid, Molnupiravir, or remdesivir.

​

More than 95 clinical trials (78 of which have been published in peer-reviewed journals)

o More than 2 dozen RCTs showing benefit from IVM
o Several Meta-analyses of RCTs showing benefit from IVM
o Many OCTs (observational controlled trials) showing benefit from IVM
o Many published reports of successful widespread government-sponsored IVM distribution programs (in Peru, Argentina, Paraguay, Brazil, Mexico, Honduras,

India, and the Philippines.

Nasopharyngeal clearance of SARS-CoV-2 was tested after single time application of PVP-I nasal irrigation (NI) at diluted concentrations of .4%, .5% and .6% and PVP-I nasal spray (NS) at diluted concentrations of .5% and .6%. 

We observed a statistically significant proportion of nasopharyngeal clearance with all strengths of PVP-I NI and PVP-I NS compared to the corresponding controls.

The only adverse event was nasal irritation recorded in two patients each in the 0.4% and 0.6% PVP-I NI groups

​Our recommendation is to use PVP-I in naopharynx (as well as oropharynx) to prevent COVID-19.

The aim of this systematic review and meta-analysis is to demonstrate that preventive vitamin D supplementation can play a protective role in the incidence of COVID-19, mortality and admission to intensive care units (ICUs).Subsequent analyses were conducted by type of subject treated (patient/healthcare workers) and type of supplementation (vitamin D vs. placebo/no treatment or high dose vs. low dose). Our meta-analysis suggests a definitive and significant association between the protective role of vitamin D and COVID-19 incidence and ICU admission.